Melanotan II

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts as a non-selective agonist at multiple melanocortin receptors, including MC1R, MC3R, MC4R, and MC5R. Its broad melanocortin receptor activity underlies its diverse biological effects spanning pigmentation, appetite regulation, sexual function, and inflammatory modulation.

At MC1R, expressed predominantly on melanocytes, MT-II stimulates melanogenesis — the production and distribution of melanin pigment — through activation of the cAMP/PKA/CREB pathway, leading to increased eumelanin synthesis and skin darkening. Research suggests this melanogenic activity occurs without UV exposure, making MT-II a valuable research tool for studying photoprotective mechanisms and melanocyte biology.

At MC3R and MC4R, expressed in the hypothalamus and other CNS regions, MT-II modulates appetite, energy homeostasis, and sexual behaviour. The MC4R-mediated effects are particularly notable: hypothalamic MC4R activation suppresses food intake and, through descending autonomic pathways, promotes penile erection and sexual arousal. This latter finding led directly to the development of PT-141 (bremelanotide), a derivative of MT-II, as an FDA-approved treatment for hypoactive sexual desire disorder. Studies indicate that MT-II's cyclic structure confers resistance to enzymatic degradation and enhanced receptor binding affinity compared to linear alpha-MSH.

Melanotan II was developed in the early 1990s at the University of Arizona by Victor Hruby and Mac Hadley as part of a research programme aimed at creating a sunless tanning agent to reduce UV-related skin cancer risk. The cyclic structure was designed to improve upon Melanotan I (afamelanotide) by enhancing receptor binding and metabolic stability. Initial studies demonstrated potent melanogenic activity — test subjects developed significant skin darkening without UV exposure.

During early clinical trials in the mid-1990s, researchers observed unexpected side effects including spontaneous penile erections and increased sexual desire in male subjects. This serendipitous discovery redirected significant research attention toward MT-II's effects on sexual function, eventually leading to the development of PT-141 (bremelanotide), which received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. Parallel research throughout the 2000s explored MT-II's effects on appetite suppression, fat metabolism, and inflammatory modulation. The peptide's CAS number is 121062-08-6, and it remains one of the most extensively studied melanocortin analogues in peptide science, serving as a pharmacological tool for dissecting melanocortin receptor biology across multiple organ systems.